Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for .
ORIC PharmaceuticalsApril 12, 2021 GMT
SOUTH SAN FRANCISCO and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, presented four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting.
ORIC-101: Glucocorticoid Receptor (GR) Antagonist ORIC-101 is a potent and selective GR antagonist, with two distinct mechanisms of action being evaluated in two Phase 1b trials in combination with: (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer.
ORIC Pharmaceuticals Inc (ORIC) Presents Posters on Four Programs at the 2021 American Association for Cancer Research
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.